HANGZHOU, China–(BUSINESS WIRE)–Ant Group today announced a major upgrade to the PC platform of its AI-native health assistant, AQ, introducing DeepSearch for cliniciansHANGZHOU, China–(BUSINESS WIRE)–Ant Group today announced a major upgrade to the PC platform of its AI-native health assistant, AQ, introducing DeepSearch for clinicians

Ant Group’s AI Health Service AQ Upgrades PC Platform with DeepSearch for Evidence-Based Clinical Decision Support

HANGZHOU, China–(BUSINESS WIRE)–Ant Group today announced a major upgrade to the PC platform of its AI-native health assistant, AQ, introducing DeepSearch for clinicians, a new capability designed to support evidence-based clinical decision-making. The service is available free of charge to clinicians and medical students.

AQ’s PC platform provides medical professionals with two core capabilities: Health Q&A and DeepSearch. It supports medical literature search, clinical practice, and research, helping reduce clinicians’ day-to-day workload while improving access to high-quality medical information.

To ensure accuracy and reliability, AQ rigorously curates its sources based on recognized levels of evidence. The platform integrates more than 36 million high-quality Chinese and international medical publications, making its clinical decision support closely aligned with real-world practice.

DeepSearch enables clinicians to rapidly access the latest clinical guidelines across specialties. Using AI-driven synthesis and organization, it structures large volumes of research based on clinical needs, significantly reducing the time required for information retrieval and review.

Beyond literature search, DeepSearch now supports evidence-based clinical decision support. In routine practice, developing treatment strategies for complex cases often requires extensive guideline consultation and literature verification. DeepSearch helps clinicians stay current with global diagnostic and therapeutic approaches, rapidly aggregates supporting evidence, and delivers logically structured, clinically relevant recommendations—enabling clearer and more robust treatment planning.

DeepSearch also features traceable citations, evidence-level filtering, and fast alignment with authoritative clinical guidelines, further easing the clinical and research burden on healthcare professionals.

AQ, known in Chinese as Ant A-Fu, is an AI-native health service launched by Ant Group in June 2025. For everyday users, AQ focuses on addressing common health concerns and supporting healthy habit formation, particularly for routine needs that do not yet require a hospital visit.

The platform connects users with digital services from more than 5,000 hospitals nationwide and provides access to online consultations with 300,000 licensed physicians.

AQ has also partnered with more than 1,000 leading physicians across China to develop AI Doctor Agents—their digital doubles—on the platform. Trained on each physician’s clinical expertise, these agents offer free, reliable answers to users’ common health questions and collectively responded to over 27 million inquiries in 2025.

As of January 2026, the AQ app has reached 30 million monthly active users and handles more than 10 million health-related queries daily, making it China’s leading AI-native health application.

About Ant Group

Ant Group is a global digital technology provider and the operator of Alipay, a leading internet services platform in China, connecting over one billion users to more than 10,000 types of consumer services from partners. Through innovative products and solutions powered by AI, blockchain and other technologies, Ant Group supports partners across industries to thrive through digital transformation in an ecosystem for inclusive and sustainable development. For more information, visit www.antgroup.com.

Contacts

Media Inquiries
Yinan Duan

[email protected]

Market Opportunity
ANTTIME Logo
ANTTIME Price(ANT)
$0.00025634
$0.00025634$0.00025634
-6.67%
USD
ANTTIME (ANT) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vitalik Buterin Withdraws 16,384 ETH to Fund Open-Source Technology and Privacy Projects

Vitalik Buterin Withdraws 16,384 ETH to Fund Open-Source Technology and Privacy Projects

TLDR: Buterin withdrew 16,384 ETH to personally fund open-source projects as Ethereum Foundation reduces spending.  The initiative supports secure hardware, privacy
Share
Blockonomi2026/01/30 16:39
What is the most promising crypto right now? A practical checklist

What is the most promising crypto right now? A practical checklist

Crypto interest often spikes after headlines. This guide helps everyday readers turn curiosity into repeatable checks that limit obvious execution risks. We focus
Share
Coinstats2026/01/30 15:52
Inside Upexi’s SOL play: staking yield and locked token deals

Inside Upexi’s SOL play: staking yield and locked token deals

The post Inside Upexi’s SOL play: staking yield and locked token deals appeared on BitcoinEthereumNews.com. Upexi is the largest public company holding Solana tokens and uses a SOL strategy to build its holdings and generate additional revenue through staking. In an interview with crypto.news, Upexi CEO Allan Marshall explains why the company executed a large equity private placement to build a crypto treasury, citing MicroStrategy’s playbook and a more accommodating U.S. policy backdrop. Summary Upexi is the largest public holder of Solana, using equity raises to build a SOL treasury and earn staking yield. Upexi CEO Allan Marshall spoke with crypto.news in an interview. Corporate strategy focuses on accretive issuances, staking, and discounted locked SOL purchases, not venture investing. Upexi markets itself as a “new institutional gateway to Solana’s (SOL) speed, scale, and rapidly growing ecosystem.” But it isn’t alone, as it joins a handful of rival companies also building Solana treasuries, while dozens of other public entities are focusing on other coins. Speaking to crypto.news, Marshall discusses strategy and market perception. He notes that Upexi is focused on accretive capital raises, staking, and discounted, locked SOL purchases rather than venture investing. He also discusses how the company measures progress through an “adjusted SOL per share” metric designed to remove timing and leverage effects. We also discuss the company’s risk management strategies, which include a buy-and-hold approach, no hedging, disciplined use of leverage, and custody with qualified providers. The entire interview transcript is below: crypto.news: Upexi is now the largest corporate holder of Solana with over 2 million SOL in treasury. Why did you make such a dramatic shift now? Was there something specific that happened in the past few months that gave you the confidence to commit so heavily to a crypto treasury at this time? Allan Marshall: Upexi did the first large-scale equity private placement to create an altcoin treasury, and there were…
Share
BitcoinEthereumNews2025/09/20 02:51